Allelic expression and quantitative RT-PCR study of TAp73 and ΔNp73 in non-Hodgkin's lymphomas

Leukemia Research

Volumn 30, Issue 2, 2006, Pages 170-177

  Cuadros, Marta ^a   Ribas, Gloria ^a   Fernández, Victoria ^a   Rivas, Carmen ^b   Benitez, Javier ^a   Martinez Delgado, Beatriz ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

Expression; Imprinting; Isoform; Lymphomas; p73; Quantitative

Indexed keywords

PROTEIN P53; PROTEIN P73;

ADULT; AGED; ALLELE; ARTICLE; CARCINOGENESIS; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LEARNING; LYMPHOCYTE; LYMPHOID CELL; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; TUMOR;

EID: 28844459666     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.024     Document Type: Article

References (45)

1. M. Kaghad, H. Bonnet, A. Yang, L. Creancier, J.C. Biscan, and A. Valent Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 90 4 1997 809 819
2. G. Melino, V. De Laurenzi, and K.H. Vousden p73: friend or foe in tumorigenesis Nat Rev Cancer 2 8 2002 605 615
3. G. Sozzi, M.G. Bertoglio, S. Pilotti, F. Rilke, M.A. Pierotti, and G. Della Porta Cytogenetic studies in primary and metastatic neuroendocrine Merkel cell carcinoma Cancer Genet Cytogenet 30 1 1988 151 158
4. T. Martinsson, A. Weith, C. Cziepluch, and M. Schwab Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region Genes Chromosomes Cancer 1 1 1989 67 78
5. P. Devilee, M. van Vliet, A. Bardoel, T. Kievits, N. Kuipers-Dijkshoorn, and P.L. Pearson Frequent somatic imbalance of marker alleles for chromosome 1 in human primary breast carcinoma Cancer Res 51 3 1991 1020 1025
6. D. Maintz, K. Fiedler, J. Koopmann, B. Rollbrocker, S. Nechev, and D. Lenartz Molecular genetic evidence for subtypes of oligoastrocytomas J Neuropathol Exp Neurol 56 10 1997 1098 1104
7. V. De Laurenzi, A. Costanzo, D. Barcaroli, A. Terrinoni, M. Falco, and M. Annicchiarico-Petruzzelli Two new p73 splice variants, gamma and delta, with different transcriptional activity J Exp Med 188 9 1998 1763 1768
8. C.A. Jost, M.C. Marin, and W.G. Kaelin Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis Nature 389 6647 1997 191 194
9. J.C. Ahomadegbe, S. Tourpin, M. Kaghad, L. Zelek, M. Vayssade, and M.C. Mathieu Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers Oncogene 19 47 2000 5413 5418
10. A. Yang, M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, and V. Dotsch p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol Cell 2 3 1998 305 316
11. Y. Tokuchi, T. Hashimoto, Y. Kobayashi, M. Hayashi, K. Nishida, and S. Hayashi The expression of p73 is increased in lung cancer, independent of p53 gene alteration Br J Cancer 80 10 1999 1623 1629
12. S. Douc-Rasy, M. Barrois, M. Echeynne, M. Kaghad, E. Blanc, and G. Raguenez DeltaN-p73alpha accumulates in human neuroblastic tumors Am J Pathol 160 2 2002 631 639
13. A.I. Zaika, N. Slade, S.H. Erster, C. Sansome, T.W. Joseph, and M. Pearl DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors J Exp Med 196 6 2002 765 780
14. I. Fillippovich, N. Sorokina, M. Gatei, Y. Haupt, K. Hobson, and E. Moallem Transactivation-deficient p73alpha (p73Delta exon2) inhibits apoptosis and competes with p53 Oncogene 20 4 2001 514 522
15. B.M. Putzer, S. Tuve, A. Tannapfel, and T. Stiewe Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript Cell Death Differ 10 5 2003 612 614
16. M. Mai, C. Qian, A. Yokomizo, D.J. Tindall, D. Bostwick, and C. Polychronakos Loss of imprinting and allele switching of p73 in renal cell carcinoma Oncogene 17 13 1998 1739 1741
17. M. Mai, A. Yokomizo, C. Qian, P. Yang, D.J. Tindall, and D.I. Smith Activation of p73 silent allele in lung cancer Cancer Res 58 11 1998 2347 2349
18. B. Martinez-Delgado, B. Melendez, M. Cuadros, M. Jose Garcia, J. Nomdedeu, and C. Rivas Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas Int J Cancer 102 1 2002 15 19
19. S.G. Chi, S.G. Chang, S.J. Lee, C.H. Lee, J.I. Kim, and J.H. Park Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer Cancer Res 59 12 1999 2791 2793
20. H. Takahashi, S. Ichimiya, Y. Nimura, M. Watanabe, M. Furusato, and S. Wakui allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma Cancer Res 58 10 1998 2076 2077
21. A. Yokomizo, M. Mai, D.J. Tindall, L. Cheng, D.G. Bostwick, and S. Naito Overexpression of the wild type p73 gene in human bladder cancer Oncogene 18 8 1999 1629 1633
22. G. Melino, L. Vitale, P. Abetti, A. Bossi, T. Fabbri, and V. Saracino Clinical investigation of hyaluronidase and nerve growth factor (NGF) at the ocular level: detailed review of the international literature Clin Ter 153 2 2002 119 126
23. T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B.M. Putzer Transactivation-deficient DeltaTA-p73 acts as an oncogene Cancer Res 62 13 2002 3598 3602
24. T.J. Grob, U. Novak, C. Maisse, D. Barcaroli, A.U. Luthi, and F. Pirnia Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53 Cell Death Differ 8 12 2001 1213 1223
25. O. Ishimoto, C. Kawahara, K. Enjo, M. Obinata, T. Nukiwa, and S. Ikawa Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73 Cancer Res 62 3 2002 636 641
26. N.N. Kartasheva, A. Contente, C. Lenz-Stoppler, J. Roth, and M. Dobbelstein p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop Oncogene 21 31 2002 4715 4727
27. T. Stiewe, C.C. Theseling, and B.M. Putzer Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis J Biol Chem 277 16 2002 14177 14185
28. J. Benard, S. Douc-Rasy, and J.C. Ahomadegbe TP53 family members and human cancers Hum Mutat 21 3 2003 182 191
29. A. Waltermann, N.N. Kartasheva, and M. Dobbelstein Differential regulation of p63 and p73 expression Oncogene 22 36 2003 5686 5693
30. E. Blint, A.C. Phillips, S. Kozlov, C.L. Stewart, and K.H. Vousden Induction of p57(KIP2) expression by p73beta Proc Natl Acad Sci USA 99 6 2002 3529 3534
31. J. Zhu, J. Jiang, W. Zhou, and X. Chen The potential tumor suppressor p73 differentially regulates cellular p53 target genes Cancer Res 58 22 1998 5061 5065
32. I. Casciano, K. Mazzocco, L. Boni, G. Pagnan, B. Banelli, and G. Allemanni Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients Cell Death Differ 9 3 2002 246 251
33. A. Tannapfel, M. Wasner, K. Krause, F. Geissler, A. Katalinic, and J. Hauss Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma J Natl Cancer Inst 91 13 1999 1154 1158
34. A.I. Saez, M.J. Artiga, C. Romero, S. Rodriguez, J.C. Cigudosa, and A. Perez-Rosado Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma Lab Invest 83 2 2003 143 152
35. B. Martinez-Delgado, M. Robledo, E. Arranz, F. Infantes, G. Echezarreta, and B. Marcos Correlation between mutations in p53 gene and protein expression in human lymphomas Am J Hematol 55 1 1997 1 8
36. J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, and O.R. Kochli Tissue microarrays for rapid linking of molecular changes to clinical endpoints Am J Pathol 159 6 2001 2249 2256
37. D. Zwahlen, M.P. Tschan, T.J. Grob, U.R. Peters, D. Fink, and W. Haenggi Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours Int J Cancer 88 1 2000 66 70
38. U.R. Peters, M.P. Tschan, K.A. Kreuzer, G. Baskaynak, U. Lass, and A. Tobler Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription- polymerase chain reaction assay and protein analysis Cancer Res 59 17 1999 4233 4236
39. U.R. Peters, U. Hasse, E. Oppliger, M. Tschan, S.T. Ong, and F.V. Rassool Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia Oncogene 18 1 1999 79 85
40. B. Banelli, I. Casciano, and M. Romani Methylation-independent silencing of the p73 gene in neuroblastoma Oncogene 19 39 2000 4553 4556
41. A.I. Zaika, S. Kovalev, N.D. Marchenko, and U.M. Moll Overexpression of the wild type p73 gene in breast cancer tissues and cell lines Cancer Res 59 13 1999 3257 3263
42. M. Korabiowska, I. Ruschenburg, H. Betke, J. Stachura, T. Schlott, and C.C. Cardo Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma Pathobiology 69 5 2001 274 280
43. S. Tuve, S.N. Wagner, B. Schittek, and B.M. Putzer Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression Int J Cancer 108 1 2004 162 166
44. N. Concin, K. Becker, N. Slade, S. Erster, E. Mueller-Holzner, and H. Ulmer Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo Cancer Res 64 7 2004 2449 2460
45. T. Stiewe, S. Tuve, M. Peter, A. Tannapfel, A.H. Elmaagacli, and B.M. Putzer Quantitative TP73 transcript analysis in hepatocellular carcinomas Clin Cancer Res 10 2 2004 626 633